VNDA

Vanda Pharmaceuticals Inc.

4.08

USD

-0.01

-0.24%

Nov 10, 15:59 UTC -5

Closed

After-Market

4.05

-0.03

-0.76%

Vanda Pharmaceuticals Inc. (VNDA) Earnings

VNDA Earnings Reports

Positive Surprise Ratio

VNDA beat 30 of 42 last estimates.

71%

Next Report

Date of Next Report

Feb 09, 2027

Estimate for Q4 26 (Revenue/ EPS)

$71.48M

-$0.30

Implied change from Q3 26 (Revenue/ EPS)

+2.38%

-18.92%

Implied change from Q4 25 (Revenue/ EPS)

+24.93%

-34.78%

Vanda Pharmaceuticals Inc. earnings per share and revenue

On Oct 28, 2026, VNDA reported earnings of -0.37 USD per share (EPS) for Q3 26, beating the estimate of -0.69 USD, resulting in a 46.81% surprise. Revenue reached 69.81 million, compared to an expected 70.59 million, with a -1.09% difference. The market reacted with a +1.25% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.30 USD, with revenue projected to reach 71.48 million USD, implying an decrease of -18.92% EPS, and increase of 2.38% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Vanda Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Vanda Pharmaceuticals Inc. reported EPS of -$0.37, beating estimates by 46.81%, and revenue of $69.81M, -1.09% below expectations.

How did the market react to Vanda Pharmaceuticals Inc.'s Q3 2026 earnings?

The stock price moved up 1.25%, changed from $4.00 before the earnings release to $4.05 the day after.

When is Vanda Pharmaceuticals Inc. expected to report next?

The next earning report is scheduled for Feb 09, 2027.

What are the forecasts for Vanda Pharmaceuticals Inc.'s next earnings report?

Based on -- analysts, Vanda Pharmaceuticals Inc. is expected to report EPS of -$0.30 and revenue of $71.48M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.